Patent Assignment
Reel/Frame 072996/0337
Security Interest
Recorded: 2025-10-01
Pages: 97
Assignors
ALNYLAM PHARMACEUTICALS, INC.
Executed: 2025-09-30
SIRNA THERAPEUTICS, INC.
Executed: 2025-09-30
Assignee
BANK OF AMERICA, N.A.
100 N TYRON STREET, CHARLOTTE, NORTH CAROLINA, 28255
Covered Properties
(776)
Rna Interference Mediated Inhibition of Hepatitis B Virus (Hbv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Application:
17/497,747 →
Publication:
US US20220275366A1
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
Rna Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Application:
18/368,620 →
Publication:
US US20240247271A1
Rna Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Application:
18/594,238 →
Publication:
US US20250066791A1
Method of treating neurodegenerative disease
Application:
10/991,286 →
Publication:
US US20050186591A1
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
Application:
18/630,504 →
Publication:
US US20250122505A1
COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES
RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION
Application:
18/077,271 →
Publication:
US US20230287424A1
G Protein-Coupled Receptor 146 (GPR146) Irna Compositions and Methods of Use Thereof
Application:
17/802,004 →
Publication:
US US20230287432A1
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
Application:
17/736,251 →
Publication:
US US20230304002A1
TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/001,050 →
Publication:
US US20230323357A1
Irna Compositions and Methods for Silencing Growth Factor Receptor Bound Protein 10 (GRB10) or Growth Factor Receptor Bound Protein 14 (GRB14) in the Liver
Application:
18/044,401 →
Publication:
US US20230332147A1
ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/001,813 →
Publication:
US US20230340485A1
Methods and Compositions for Treating Primary Hyperoxaluria
Application:
18/302,855 →
Publication:
US US20230392155A1
G Protein-Coupled Receptor 75 (GPR75) Irna Compositions and Methods of Use Thereof
Application:
18/129,923 →
Publication:
US US20230392156A1
Methods and Compositions for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Application:
18/324,191 →
Publication:
US US20230407312A1
Mucin 5B (MUC5B) Irna Compositions and Methods of Use Thereof
Application:
18/136,386 →
Publication:
US US20230416736A1
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/900,921 →
Publication:
US US20230416748A1
Snca Irna Compositions and Methods of Use Thereof for Treating or Preventing Snca-Associated Neurodegenerative Diseases
Application:
18/247,314 →
Publication:
US US20240011032A1
Complement Factor B (Cfb) Irna Compositions and Methods of Use Thereof
Application:
17/974,598 →
Publication:
US US20240018515A1
Dipeptidyl Peptidase 4 (DPP4) Irna Compositions and Methods of Use Thereof
Application:
18/125,167 →
Publication:
US US20240067972A1
METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
Application:
18/299,220 →
Publication:
US US20240100080A1
Polynucleotide Agents Targeting Programmed Cell Death 1 Ligand 1 (Pd-L1) and Methods of Use Thereof
Application:
18/202,328 →
Publication:
US US20240102020A1
Compositions and Methods for Inhibition of Expression of Apolipoprotein C-Iii (APOC3) Genes
Application:
18/199,390 →
Publication:
US US20240110180A1
COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/206,116 →
Publication:
US US20240117348A1
iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)
Application:
18/263,155 →
Publication:
US US20240117349A1
Prion Protein (Prnp) Irna Compositions and Methods of Use Thereof
Application:
18/236,437 →
Publication:
US US20240124882A1
GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/243,133 →
Publication:
US US20240132895A1
Solute Carrier Family Member Irna Compositions and Methods of Use Thereof
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES
Application:
18/131,892 →
Publication:
US US20240150767A1
Complement Component C5 Irna Compositions and Methods of Use Thereof
Application:
18/144,275 →
Publication:
US US20240175017A1
DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA
Application:
18/548,634 →
Publication:
US US20240175028A1
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/499,495 →
Publication:
US US20240182905A1
ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Angiopoietin-Like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Stearoyl-Coa Desaturase 5 (SCD5) Irna Agent Compositions and Methods of Use Thereof
Application:
18/550,669 →
Publication:
US US20240200077A1
Redirecting Risc for Rna Editing
Application:
18/556,180 →
Publication:
US US20240209339A1
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Proline Dehydrogenase 2 (PRODH2) Irna Compositions and Methods of Use Thereof
Application:
18/373,397 →
Publication:
US US20240209372A1
ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/551,668 →
Publication:
US US20240209373A1
iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN
Application:
18/556,583 →
Publication:
US US20240209374A1
Compositions and Methods for Treating Transthyretin (Ttr) Mediated Amyloidosis
Application:
18/385,005 →
Publication:
US US20240218369A1
Methods of Treating Transthyretin (Ttr) Mediated Amyloidosis
Application:
18/382,562 →
Publication:
US US20240230644A1
Methods and Compositions for Treating an Angiotensinogen- (Agt-) Associated Disorder
Application:
18/542,950 →
Publication:
US US20240247266A1
Carbohydrate Conjugated Rna Agents and Process for Their Preparation
SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR 6 (STAT6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/383,941 →
Publication:
US US20240254484A1
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
Application:
18/502,670 →
Publication:
US US20240254486A1
MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/581,511 →
Publication:
US US20240254491A1
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Sodium-Glucose Cotransporter-2 (SGLT2) Irna Compositions and Methods of Use Thereof
Application:
18/389,245 →
Publication:
US US20240271144A1
RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
Application:
18/509,440 →
Publication:
US US20240279652A1
FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF
Application:
18/547,102 →
Publication:
US US20240279653A1
GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/509,583 →
Publication:
US US20240287524A1
ATXN2 Irna Compositions and Methods of Use Thereof for Treating or Preventing ATXN2-Associated Neurodegenerative Diseases
Application:
18/007,007 →
Publication:
US US20240294906A1
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/509,453 →
Publication:
US US20240294911A1
COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/519,295 →
Publication:
US US20240294912A1
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Application:
18/218,638 →
Publication:
US US20240301406A1
iRNA Compositions and Methods for Silencing Filamin A (FLNA)
Application:
18/572,553 →
Publication:
US US20240301418A1
Leucine-Rich Repeat Kinase 2 (LRRK2) Irna Agent Compositions and Methods of Use Thereof
Application:
18/575,157 →
Publication:
US US20240301426A1
Metabolic Disorder-Associated Target Gene Irna Compositions and Methods of Use Thereof
Application:
18/403,912 →
Publication:
US US20240309370A1
Compositions and Methods for Treating or Preventing Stargardt's Disease and/or Retinal Binding Protein 4 (RBP4)-Associated Disorders
Application:
18/531,914 →
Publication:
US US20240309375A1
Compositions and Methods for Inhibiting Expression of TMPRSS6 Gene
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/376,217 →
Publication:
US US20240309387A1
3'-Oh Rna-Containing Oligonucleotide Deprotection
Application:
18/613,537 →
Publication:
US US20240317794A1
Compositions and Methods for Silencing MYOC Expression
Application:
18/572,486 →
Publication:
US US20240318175A1
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/525,922 →
Publication:
US US20240318184A1
2'-Modified Nucleoside Based Oligonucleotide Prodrugs
Application:
18/259,887 →
Publication:
US US20240336914A1
Cyclic-Disulfide Modified Phosphate Based Oligonucleotide Prodrugs
Application:
18/259,884 →
Publication:
US US20240343746A1
BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/405,072 →
Publication:
US US20240344066A1
Methods and Compositions for Treating Subjects Having or at Risk of Developing a Non-Primary Hyperoxaluria Disease or Disorder
Application:
18/403,862 →
Publication:
US US20240344070A1
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/301,089 →
Publication:
US US20240344073A1
Extrahepatic Delivery
Application:
18/651,230 →
Publication:
US US20240358738A1
Renal Injury Biomarkers as Biomarkers for Acute Hepatic Porphyria (Ahp)
Application:
18/623,281 →
Publication:
US US20240360454A1
Extra-Hepatic Delivery Irna Compositions and Methods of Use Thereof
Application:
18/631,104 →
Publication:
US US20240360455A1
Huntingtin (Htt) Irna Agent Compositions and Methods of Use Thereof
Application:
18/636,371 →
Publication:
US US20240368594A1
COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/405,281 →
Publication:
US US20240376477A1
Irna Compositions and Methods for Silencing Angiotensinogen (Agt)
Application:
18/427,082 →
Publication:
US US20240392294A1
Biodegradable Lipids for the Delivery of Active Agents
Application:
18/541,755 →
Publication:
US US20240398956A1
FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/677,062 →
Publication:
US US20240401056A1
Integrin Targeting Ligands for Ocular Delivery of Rnai Compounds
Application:
18/576,572 →
Publication:
US US20240409927A1
Transthyretin (Ttr) Irna Compositions and Methods of Use Thereof
Application:
18/600,902 →
Publication:
US US20240409929A1
iRNA Compositions and Methods for Targeting ANGPTL7
Application:
18/697,297 →
Publication:
US US20240409943A1
Kisspeptin 1 (KISS1) Irna Compositions and Methods of Use Thereof
Application:
18/620,251 →
Publication:
US US20240425854A1
Huntingtin (Htt) Irna Agent Compositions and Methods of Use Thereof
Application:
18/631,105 →
Publication:
US US20250011776A1
APP iRNA Compositions and Methods of Use Thereof for Treating or Preventing Diseases Characterized by Enlarged Endosomes
Application:
18/690,200 →
Publication:
US US20250011778A1
LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/637,500 →
Publication:
US US20250017953A1
Irna Compositions and Methods for Silencing Complement Component 3 (C3)
Application:
18/605,975 →
Publication:
US US20250019698A1
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
Application:
18/637,183 →
Publication:
US US20250019699A1
Simple Chemical Approaches to Introduce 2,6-Diaminopurine and 2-Aminoadenine Conjugates into Oligonucleotides
Application:
18/577,888 →
Publication:
US US20250025564A1
Complement Factor B (Cfb) Irna Compositions and Methods of Use Thereof
Application:
18/598,006 →
Publication:
US US20250027080A1
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
Application:
18/630,441 →
Publication:
US US20250034566A1
Cell Death-Inducing Dffa-Like Effector B (Cideb) Irna Compositions and Methods of Use Thereof
Application:
18/687,251 →
Publication:
US US20250034567A1
STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/644,183 →
Publication:
US US20250043279A1
3-Hydroxy-3-Methylglutaryl-Coa Reductase (Hmgcr) Irna Compositions and Methods of Use Thereof
Application:
18/423,377 →
Publication:
US US20250043289A1
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/648,530 →
Publication:
US US20250051765A1
iRNA Compositions and Methods for Silencing MYLIP
Application:
18/717,329 →
Publication:
US US20250051767A1
Inhibin Subunit Beta E (Inhbe) Modulator Compositions and Methods of Use Thereof
Application:
18/607,663 →
Publication:
US US20250051779A1
Tunable Reversir Tm Compounds
Application:
18/659,729 →
Publication:
US US20250059536A1
Snca-Targeting Sirna Compositions for Treating Snca-Associated Disease
Application:
18/898,882 →
Publication:
US US20250059541A1
Cell Death-Inducing Dffa-Like Effector B (Cideb) Irna Compositions and Methods of Use Thereof
Compositions and Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Application:
18/434,928 →
Publication:
US US20250064936A1
ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/780,571 →
Publication:
US US20250064943A1
Oligonucleotide-Ligand Conjugates and Process for Their Preparation
Application:
18/427,072 →
Publication:
US US20250075208A1
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
Application:
18/744,959 →
Publication:
US US20250075211A1
Peptide Ligands for Cns and Ocular Delivery of Rnai Compounds
Application:
18/293,269 →
Publication:
US US20250075217A1
Heparin Sulfate Biosynthesis Pathway Enzyme Irna Agent Compositions and Methods of Use Thereof
Application:
18/777,691 →
Publication:
US US20250084417A1
Compositions and Methods for Silencing Carbonic Anhydrase 2 Expression
Application:
18/820,997 →
Publication:
US US20250084418A1
Snca-Targeting Sirna Compositions for Treating Snca-Associated Disease
Application:
18/978,602 →
Publication:
US US20250115911A1
iRNA Compositions and Methods for Silencing ANGPTL4
Application:
18/691,742 →
Publication:
US US20250136978A1
Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use Thereof
Application:
18/837,453 →
Publication:
US US20250171777A1
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
Application:
18/934,287 →
Publication:
US US20250171785A1
High Mobility Group Box-1 (HMGB1) Irna Compositions and Methods of Use Thereof
Application:
18/768,261 →
Publication:
US US20250188456A1
Multiplexing Targeting Ligands Through Click Chemistry at the Anomeric Site of Sugars
Application:
18/577,948 →
Publication:
US US20250188470A1
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/921,120 →
Publication:
US US20250188475A1
Modified Rna Agents with Reduced Off-Target Effect
Application:
19/025,271 →
Publication:
US US20250205272A1
Polynucleotide Agents Targeting Complement Component C5 and Methods of Use Thereof
Application:
18/792,638 →
Publication:
US US20250207128A1
Modified Rna Agents with Reduced Off-Target Effect
Application:
18/968,749 →
Publication:
US US20250207131A1
Oligonucleotides with 2'-Deoxy-2'-F-2'-C-Methyl Nucleotides
Application:
18/702,640 →
Publication:
US US20250223588A1
Multi-Targeted Single Entity Conjugates
Application:
19/003,611 →
Publication:
US US20250236871A1
Universal Non-Targeting Sirna Compositions and Methods of Use Thereof
Application:
19/053,526 →
Publication:
US US20250243490A1
XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/810,894 →
Publication:
US US20250250572A1
Reversir Tm Compounds
Application:
19/019,685 →
Publication:
US US20250257351A1
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/986,819 →
Publication:
US US20250257358A1
Bis-Rnai Compounds for Cns Delivery
Application:
18/577,377 →
Publication:
US US20250270562A1
Therapeutic Compositions
Compositions And Methods For Inhibiting Expression Of The HAMP Gene
Single-Stranded and Double-Stranded Oligonucleotides Comprising a 2-Arylpropyl Moiety
Conserved Hbv and Hcv Sequences Useful for Gene Silencing
Hepatitis C Dsrna Effector Molecules, Expression Constructs, Compositions, and Methods of Use
Poly(Amide) Polymers for the Delivery of Oligonucleotides
Modified 5' Diphosphate Nucleosides and Oligomeric Compounds Prepared Therefrom
Targeting Opposite Strand Replication Intermediates of Single-Stranded Viruses by Rnai
Nucleic Acid Chemical Modifications
Monomers and Oligonucleotides Comprising Cycloaddition Adduct(S)
SERPINA1 Sirnas: Compositions of Matter and Methods of Treatment
Glycoconjugates of RNA Interference Agents
Oligonucleotide End Caps
Monomers and Oligonucleotides Comprising Cycloaddition Adduct(S)
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Endosomal Cleavable Linkers
Application:
17/668,917 →
Publication:
US US20220177885A1
Modified Rna Agents with Reduced Off-Target Effect
Application:
17/937,256 →
Publication:
US US20230256001A1
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE
Application:
18/761,504 →
Publication:
US US20250197855A1
MODIFIED RNAi AGENTS
Application:
19/085,209 →
Publication:
US US20250213720A1
SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/907,649 →
Publication:
US US20250276001A1
Methods and Compositions for Treating a Proprotein Convertase Subtilisin Kexin (PCSK9) Gene-Associated Disorder
Application:
19/214,546 →
Publication:
US US20250277218A1
Modified Double Stranded Oligonucleotides
Application:
18/262,302 →
Publication:
US US20250283071A1
ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/862,839 →
Publication:
US US20250283079A1
Compositions and Methods for Inhibiting Expression of Xbp-1 Gene
Compositions And Methods For Inhibiting Expression Of Factor V
Lipid Formulation
Microrna Compositions and Methods
Compositions and Methods for Increasing Erythropoietin (Epo) Production
Systems and Methods for Ionization
Methods and Compositions for Treating a Bleeding Event in a Subject Having Hemophilia
Application:
17/878,884 →
Publication:
US US20230158058A1
Modified Double Stranded Oligonucleotide
AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/314,909 →
Publication:
US US20220002724A1
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/528,234 →
Publication:
US US20220202847A1
Oral Delivery of Oligonucleotides
Application:
17/611,761 →
Publication:
US US20220211743A1
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
Application:
17/392,122 →
Publication:
US US20220213473A1
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/588,393 →
Publication:
US US20220228151A1
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
Application:
17/639,881 →
Publication:
US US20220290152A1
Delivery of Oligonucleotides to the Striatum
Application:
17/619,633 →
Publication:
US US20220307024A1
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Biodegradable Lipids for the Delivery of Active Agents
Application:
17/250,952 →
Publication:
US US20220370356A1
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Modified Oligonucleotides
Compositions and Methods for Silencing UGT1A1 Gene Expression
Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Application:
17/579,655 →
Publication:
US US20220403394A1
XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/683,423 →
Publication:
US US20220411801A1
Methods and Compositions for Treating an Angiotensinogen- (Agt-) Associated Disorder
Application:
17/743,498 →
Publication:
US US20230002765A1
PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Extrahepatic Delivery
Application:
17/774,477 →
Publication:
US US20230016929A1
Synthesis of 3 -Rna Oligonucleotides
Application:
17/779,706 →
Publication:
US US20250325575A2
Neurofilament Light Chain (Nfl) as a Biomarker for Transthyretin Amyloidosis Polyneuropathy
Application:
17/672,771 →
Publication:
US US20230024849A1
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/668,413 →
Publication:
US US20230032974A1
Compositions and Methods for Silencing DNAJB1-Prkaca Fusion Gene Expression
Application:
17/773,508 →
Publication:
US US20230040920A1
ATAXIN3 (ATXN3) Rnai Agent Compositions and Methods of Use Thereof
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Chirally-Enriched Double-Stranded Rna Agents
Application:
17/982,819 →
Publication:
US US20230122244A1
Mannan Binding Lectin Serine Peptidase 2 (MASP2) Irna Compositions and Methods of Use Thereof
LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/794,637 →
Publication:
US US20230126233A1
Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/907,366 →
Publication:
US US20230126881A1
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/956,882 →
Publication:
US US20230133147A1
Angiopoietin-Like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Application:
17/873,239 →
Publication:
US US20230136552A1
Compositions and Methods for Silencing Vegf-a Expression
Application:
17/798,156 →
Publication:
US US20230136787A1
ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Silencing SCN9A Expression
Application:
17/995,699 →
Publication:
US US20230159933A1
Compositions and Methods for Treating Subjects Having a Heterozygous Alanine-Glyoxylate Aminotransferase Gene (Agxt) Variant
Application:
17/945,151 →
Publication:
US US20230183706A1
Compositions and Methods for Inhibiting MARC1 Gene Expression
Application:
17/999,320 →
Publication:
US US20230183707A1
Compositions and Methods for Silencing DNAJC15 Gene Expression
Application:
17/907,664 →
Publication:
US US20230190785A1
APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/974,596 →
Publication:
US US20230193268A1
Transmembrane Serine Protease 2 (TMPRSS2) Irna Compositions and Methods of Use Thereof
MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
17/995,035 →
Publication:
US US20230203486A1
Sirna Compositions and Methods for Silencing Gpam (Glycerol-3-Phosphate Acyltransferase 1, Mitochondrial) Expression
Application:
18/001,065 →
Publication:
US US20230203496A1
Biodegradable Lipids for the Delivery of Active Agents
Application:
18/304,097 →
Publication:
US US20230256098A1
Circular siRNAs
Application:
18/015,202 →
Publication:
US US20230257745A1
Compositions and Methods for Inhibiting Expression of Transthyretin
Application:
19/013,039 →
Publication:
US US20250376682A1
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
15/695,254 →
Publication:
US US20180087058A1
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
Application:
16/052,719 →
Publication:
US US20190119674A1
Modified Double-Stranded Rna Agents
Application:
19/079,175 →
Publication:
US US20260098263A1
Methods of Treating Transthyretin (TTR) Mediated Amyloidosis
Application:
17/362,631 →
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
16/694,244 →
Publication:
US US20200080088A1
Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
15/800,517 →
Publication:
US US20180100150A1
Factor Xii (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) Irna Compositions and Methods of Use Thereof
Application:
19/211,821 →
Publication:
US US20260015613A1
Reversir Tm Compounds
Application:
15/537,083 →
Publication:
US US20170369872A1
Polynucleotide Agents Targeting Angiotensinogen (Agt) and Methods of Use Thereof
Application:
16/998,046 →
Publication:
US US20200384011A1
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/077,500 →
Publication:
US US20260027146A1
Xanthine Dehydrogenase (Xdh) Irna Compositions and Methods of Use Thereof
Application:
15/747,571 →
Publication:
US US20180216114A1
Methods and Compositions for Treating a Proprotein Convertase Subtilisin Kexin (PCSK9) Gene-Associated Disorder
Application:
15/895,023 →
Publication:
US US20180187198A1
Methods and Compositions for Treating a Proprotein Convertase Subtilisin Kexin (PCSK9) Gene-Associated Disorder
Application:
16/929,470 →
Publication:
US US20210163951A1
Methods and Compositions for Treating a Proprotein Convertase Subtilisin Kexin (PCSK9) Gene-Associated Disorder
Application:
19/089,092 →
Polynucleotide Agents Targeting Programmed Cell Death 1 Ligand 1 (Pd-L1) and Methods of Use Thereof
Application:
19/273,195 →
Publication:
US US20260103715A1
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Application:
16/307,963 →
Publication:
US US20190256845A1
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Application:
17/069,926 →
Publication:
US US20210171946A1
LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
16/716,705 →
Publication:
US US20200113927A1
LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
16/811,476 →
Publication:
US US20200206258A1
Methods and Compositions for Treating a Bleeding Event in a Subject Having Hemophilia
Application:
16/630,044 →
Publication:
US US20200163987A1
Compositions and Methods for Treating Transthyretin (Ttr) Mediated Amyloidosis
Application:
19/181,733 →
Publication:
US US20260053839A1
17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/202,677 →
Publication:
US US20250333737A1
Compositions and Methods for Improving Strand Biased
Application:
18/921,732 →
Publication:
US US20250163417A1
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
Application:
19/247,022 →
Publication:
US US20260167961A1
SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/231,316 →
Publication:
US US20260000701A1
Structurally Defined Sirna-Dual Variable Domain Immunoglobulin Conjugates
Application:
17/621,029 →
Publication:
US US20230049529A1
Compositions and Methods for Silencing Myoc Expression
Application:
17/995,568 →
Publication:
US US20230295622A1
Complement Component C3 Irna Compositions and Methods of Use Thereof
Application:
19/236,016 →
Publication:
US US20260049312A1
Coronavirus Irna Compositions and Methods of Use Thereof
Application:
19/274,710 →
Publication:
US US20260159837A1
Reversir Molecules and Methods of Use Thereof
Application:
19/281,945 →
Publication:
US US20260055413A1
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/322,891 →
Publication:
US US20260218189A1
Modified Oligonucleotides
Application:
18/272,448 →
Publication:
US US20240116973A1
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Application:
18/525,924 →
Publication:
US US20240240182A1
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/252,346 →
Publication:
US US20260028631A1
Aminooxy Click Chemistry (Aocc): a Versatile Conjugation Approach
Application:
18/576,561 →
Publication:
US US20250304613A1
Monomers and Methods for Synthesis of Modified Oligonucleotides
Application:
18/878,308 →
Publication:
US US20250382324A1
Single-Stranded Loop Oligonucleotides
Application:
18/864,172 →
Publication:
US US20250304957A1
Cyclic-Disulfide Modified Phosphate Based Oligonucleotide Prodrugs
Application:
18/877,507 →
ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY
Application:
19/235,730 →
Publication:
US US20260048130A1
PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/118,612 →
PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/293,414 →
Publication:
US US20260035702A1
17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
19/077,157 →
Publication:
US US20250304967A1
Extrahepatic Delivery
Application:
63/566,106 →
Modified Oligonucleotides and Double-Stranded Rnas
Application:
19/115,562 →
Publication:
US US20260132404A1
Modified Oligonucleotides and Double-Stranded Rnas
Application:
63/521,256 →
Modified Double-Stranded Rna Agents
Application:
19/115,987 →
Publication:
US US20260218177A1
Six Membered Ring Containing Oligomers
Application:
19/150,817 →
ACTIVIN A RECEPTOR TYPE 1C (ACVR1C) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
63/694,377 →
Methods and Compositions for Treating an Angiotensinogen- (Agt-) Associated Disorder
Application:
63/608,909 →
Methods and Compositions for Treating Ketohexokinase (Khk)-Associated Diseases
Application:
63/608,906 →
Methods and Compositions for Treating Ketohexokinase (Khk)-Associated Diseases
Application:
63/659,007 →
Methods and Compositions for Treating Transthyretin (Ttr)- Associated Diseases
Application:
63/608,908 →
Method for Separating Oligonucleotides
Application:
63/641,046 →
Dual Conjugate Compounds for Extrahepatic Delivery
Application:
63/659,097 →
5’-Modified Monomers, Oligonucleotides and Double-Stranded Rnas
Application:
63/660,020 →
5’-Modified Monomers, Oligonucleotides and Double-Stranded Rnas
Application:
63/761,405 →
5’-Modified Monomers, Oligonucleotides and Double-Stranded Rnas
Application:
63/660,129 →
5’-Modified Monomers, Oligonucleotides and Double-Stranded Rnas
Application:
63/705,390 →
SOLUTE CARRIER FAMILY 27 MEMBER 5 (SLC27A5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
63/654,523 →
Integrin Ligands for Extrahepatic Delivery
Application:
63/662,610 →
Dystrophy Myotonic Protein Kinase (Dmpk) Irna Compositions and Methods of Use Thereof
Application:
63/659,098 →
Dystrophy Myotonic Protein Kinase (Dmpk) Irna Compositions and Methods Ofuse Thereof
Application:
63/760,695 →
siRNAs Targeting Complement Factor H-Related (CFHR) Gene Transcripts and Methods of Use
Application:
63/716,577 →
PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
63/782,976 →
Snca Irna Formulations and Methods of Use Thereof
Application:
63/708,119 →
MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA FORMULATIONS AND METHODS OF USE THEREOF
Application:
63/708,234 →
CD81 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Application:
63/728,719 →
Rna Interference Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acids (Sina)
Systemic Delivery of Myostatin Short Interfering Nucleic Acids (Sina) Conjugated to a Lipophilic Moiety
Application:
19/027,971 →
Publication:
US US20250312490A1
Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules
Rna Interference Mediated Inhibition of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery
RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
Method for Rapidly Evaluating Performance of Short Interfering Rna with Novel Chemical Modifications
Membrane Lytic Poly(Amido Amine) Polymers for the Delivery of Oligonucleotides
RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression Using Short Interfering Nucleic Acid (siNA)
Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery
Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Novel Low Molecular Weight Cyclic Amine Containing Cationic Lipids for Oligonucleotide Delivery
Segmented Micro Rna Mimetics
Novel Cationic Lipids with Various Head Groups for Oligonucleotide Delivery
Rna Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Single-Stranded RNAi Agents Containing an Internal, Non-Nucleic Acid Spacer
Rna Interference Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acids (Sina)
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Rna Interference Mediated Inhibition of Isocitrate Dehydrogenase (IDH1) Gene Expression
Novel Diester and Triester Based Low Molecular Weight, Biodegradeable Cationic Lipids for Oligonucleotide Delivery
DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
Rna Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Rna Interference Mediated Inhibition of Hepatitis B Virus (Hbv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Novel Tetragalnac Containing Conjugates and Methods for Delivery of Oligonucleotides
DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
Novel Cationic Lipids with Various Head Groups for Oligonucleotide Delivery
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Novel Tetragalnac and Peptide Containing Conjugates and Methods for Delivery of Oligonucleotides
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Novel Cationic Lipids for Oligonucleotide Delivery
Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Segmented Micro Rna Mimetics
Novel Low Molecular Weight Cyclic Amine Containing Cationic Lipids for Oligonucleotide Delivery
Single-Stranded Rnai Agents Containing an Internal, Non-Nucleic Acid Spacer
Rna Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Novel Diester and Triester Based Low Molecular Weight, Biodegradeable Cationic Lipids for Oligonucleotide Delivery
Rna Interference Mediated Inhibition of Hepatitis B Virus (Hbv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Systemic Delivery of Myostatin Short Interfering Nucleic Acids (Sina) Conjugated to a Lipophilic Moiety
Rna Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Novel Diester and Triester Based Low Molecular Weight, Biodegradeable Cationic Lipids for Oligonucleotide Delivery
Novel Low Molecular Weight Cyclic Amine Containing Cationic Lipids for Oligonucleotide Delivery
Segmented Micro Rna Mimetics
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Rna Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Single-Stranded Rnai Agents Containing an Internal, Non-Nucleic Acid Spacer
Short Interfering Nucleic Acid (Sina) Compositions
SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (siNA) CONJUGATED TO A LIPOPHILIC MOIETY
SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE (3dT)
Rna Interference Mediated Inhibition of Hepatitis B Virus (Hbv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
Rna Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Systemic Delivery of Myostatin Short Interfering Nucleic Acids (Sina) Conjugated to a Lipophilic Moiety
Short Interfering Nucleic Acid (Sina) Compositions
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
Rna Interference Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acids (Sina)
Rna Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules
Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules
Membrane Lytic Poly(Amido Amine) Polymers for the Delivery of Oligonucleotides
Post-Synthetic Chemical Modification of Rna at the 2'-Position of the Ribose Ring via "Click" Chemistry
Method for Rapidly Evaluating Performance of Short Interfering Rna with Novel Chemical Modifications
Novel Tetragalnac and Peptide Containing Conjugates and Methods for Delivery of Oligonucleotides
Novel Tetragalnac Containing Conjugates and Methods for Delivery of Oligonucleotides
Novel Tetragalnac and Peptide Containing Conjugates and Methods for Delivery of Oligonucleotides
POST-SYNTHETIC ORTHOGANAL AMIDATION PLUS METAL CATALYZED AZIDE-ALKYNE CYCLOADDITION CLICK CHEMISTRY ON siRNA
Novel Tetragalnac and Peptide Containing Conjugates and Methods for Delivery of Oligonucleotides
Novel Tetragalnac and Peptide Containing Conjugates and Methods for Delivery of Oligonucleotides
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism
Rnai Modulation of Tgf-Beta and Therapeutic Uses Thereof
Lipophilic Conjugated Irna Agents
Compositions and Methods for Inhibiting Expression of NAV1.8 Gene
Complex for Transferring an Anionic Substance into a Cell
Nuclease Resistant Double-Stranded Ribonucleic Acid
Dsrna Compositions and Methods for Treating Hpv Infection
Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
Rnai Modulation of Rsv and Therapeutic Uses Thereof
Multiple Rna Polymerase Iii Promoter Expression Constructs
Rnai Modulation of the Bcr-Abl Fusion Gene and Uses Thereof
Method of Stimulating an Immune Response and Inhibiting Expression of a Gene Using an Oligonucleotide
Rnai Modulation of Mll-AF4 and Uses Thereof
Irna Agents Targeting CCR5 Expressing Cells and Uses Thereof
Processes and Reagents for Desilylation of Oligonucleotides
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Compositions and Methods for Inhibiting Expression of the Myc Gene
Rnai Modulation of Rsv and Therapeutic Uses Thereof
Compositions and Methods for Inhibiting Expression of the Hamp Gene
Compositions and Methods for Inhibiting Expression of Transthyretin
Rnai Modulation of Apob and Uses Thereof
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
Enhancement of Influenza Gene Expression
Rnai Modulation of Rsv and Therapeutic Uses Thereof
Compositions and Methods for Inhibiting Expression of the Hamp Gene
Lipid Formulated Dsrna Targeting the PCSK9 Gene
Compositions and Methods for Inhibiting Expression of CD45 Gene
Gnaq Targeted Dsrna Compositions and Methods for Inhibiting Expression
Compositions and Methods for Inhibiting Expression of Xbp-1 Gene
Conserved Hbv and Hcv Sequences Useful for Gene Silencing
Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
Ligand-Conjugated Monomers
Methods and Compositions for Prevention or Treatment of Rsv Infection
Compositions and Methods for Inhibiting Expression of a Gene from the Jc Virus
Irna Agents with Biocleavable Tethers
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Compositions and Methods for Inhibiting Expression of CD274/Pd-L1 Gene
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
Compositions And Methods For Inhibiting Expression Of An RNA From West Nile Virus
RNAi Modulation of APOB and Uses Thereof
Lipid Formulated Dsrna Targeting the PCSK9 Gene
Hepatitis C Dsrna Effector Molecules, Expression Constructs, Compositions, and Methods of Use
Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
Compositions and Methods for Inhibiting Expression of Transthyretin
Therapeutic Compositions
Compositions and Methods for Inhibiting Expression of XBP-1 Gene
Compositions And Methods For Inhibiting Expression Of The HAMP Gene
Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Lipid Formulated Compositions and Methods for Inhibiting Expression of EG5 and Vegf Genes
Rnai Modulation of Rsv and Therapeutic Uses Thereof
Glycoconjugates of RNA Interference Agents
GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION
Compositions and Methods for Inhibiting Expression of CD45 Gene
5' Phosphate Mimics
Chemical Modifications of Monomers and Oligonucleotides with Cycloaddition
Nucleic Acid Chemical Modifications
Compositions and Methods for Inhibiting Expression of EG5 and Vegf Genes
Biodegradable Lipids for the Delivery of Active Agents
Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
Process for Triphosphate Oligonucleotide Synthesis
Post-Transcriptional Gene Silencing Using Expressed Double Stranded Rna
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE
Biodegradable Lipids for the Delivery of Active Agents
Compositions and Methods for Inhibiting Expression of Factor Vii Gene
Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes
Compositions and Methods for Inhibiting Expression of the Hamp Gene
Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR)
SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Inhibiting Expression of Klf-1 and BCL11A Genes
Methods and Compositions for Prevention or Treatment of Rsv Infection
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
Compositions and Methods for Inhibiting Expression of TMPRSS6 Gene
Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
Dual Targeting Sirna Agents
RNAi Modulation Of ApoB And Uses Thereof
Monomers and Oligonucleotides Comprising Cycloaddition Adduct(S)
Compositions and Methods for Inhibiting Expression of Mylip/Idol Gene
Compositions and Methods for Inhibiting Expression of an RNA from West Nile Virus
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid a Gene
Compositions and Method for Inhibiting Hepcidin Antimicrobial Peptide (HAMP) or HAMP-Related Gene Expression
Compositions and Methods for Inhibiting Expression of Transthyretin
Complement Component C5 Irna Compositions and Methods of Use Thereof
Methods and Compositions for Delivery of Active Agents
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
MODIFIED iRNA AGENTS
Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Lipid Formulated Compositions and Methods for Inhibiting Expression of EG5 and Vegf Genes
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Stable Non-Aggregating Nucleic Acid Lipid Particle Formulations
Compositions and Methods for Inhibiting Expression of CD274/Pd-L1 Gene
Compositions And Methods For Inhibiting Expression of Factor V
Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
Compositions And Methods For Inhibiting Expression Of The HAMP Gene
Oligonucleotide End Caps
GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Biodegradable Lipids for the Delivery of Active Agents
Improved Nucleic Acid Lipid Particle Formulations
Di-Aliphatic Substituted Pegylated Lipids
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Modified Rnai Agents
Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes
Angiopoietin-Like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MODIFIED RNAi AGENTS
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
Complement Component C5 Irna Compositions and Methods of Use Thereof
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
Compositions and Methods for Inhibiting Expression of CD274/Pd-L1 Gene
Compositions and Methods Directed to Treating Liver Fibrosis
GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION
Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes
Pegylated Lipids and Their Use for Drug Delivery
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Methods of Treating Transthyretin (TTR) Mediated Amyloidosis
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
Carbohydrate Conjugated Rna Agents and Process for Their Preparation
Compositions and Methods for Inhibiting Expression of TMPRSS6 Gene
RNAi AGENTS MODIFIED AT THE 4'-C POSITION
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
5' Phosphate Mimics
Methods and Compositions for Treating Insects
Compositions and Methods for the Manufacture of Lipid Nanoparticles
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Modified Double-Stranded Rna Agents
Compositions and Methods for Increasing Erythropoietin (Epo) Production
Compositions and Methods for Inhibiting Expression of Transthyretin
Dosages and Methods for Delivering Lipid Formulated Nucleic Acid Molecules
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Biodegradable Lipids for the Delivery of Active Agents
Ketohexokinase (Khk) Irna Compositions and Methods of Use Thereof
Polynucleotide Agents Targeting Complement Component C5 and Methods of Use Thereof
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Complement Component Irna Compositions and Methods of Use Thereof
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
Compositions and Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Insulin-Like Growth Factor Binding Protein, Acid Labile Subunit (Igfals) Compositions and Methods of Use Thereof
Compositions and Methods for Inhibiting Expression of Factor V
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
Hepatitis B Virus (Hbv) Irna Compositions and Methods of Use Thereof
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Polynucleotide Agents Targeting Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) and Methods of Use Thereof
Modified Double-Stranded Rna Agents
Modified Double-Stranded Rna Agents
HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MODIFIED RNAi AGENTS
Compositions and Methods Directed to Treating Liver Fibrosis
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
Compositions and Methods for Inhibiting Expression of CD274/Pd-L1 Gene
STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Oligonucleotide-Ligand Conjugates and Process for Their Preparation
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Methods and Compositions for Treating a Proprotein Convertase Subtilisin Kexin (PCSK9) Gene-Associated Disorder
Polynucleotide Agents Targeting Factor Xii (Hageman Factor) (F12) and Methods of Use Thereof
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Oligonucleotides Comprising Acyclic and Abasic Nucleosides and Analogs
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Myostatin Irna Compositions and Methods of Use Thereof
FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SERPINA1 Sirnas: Compositions of Matter and Methods of Treatment
Polynucleotide Agents Targeting Hydroxyacid Oxidase (Glycolate Oxidase, HAO1) and Methods of Use Thereof
GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
Polynucleotide Agents Targeting Aminolevulinic Acid Synthase-1 (ALAS1) and Uses Thereof
Polynucleotide Agents Targeting Programmed Cell Death 1 Ligand 1 (Pd-L1) and Methods of Use Thereof
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Angiotensinogen (Agt) Irna Compositions and Methods of Use Thereof
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Multi-Targeted Single Entity Conjugates
Hepatitis B Virus (Hbv) Irna Compositions and Methods of Use Thereof
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Biodegradable Lipids for the Delivery of Active Agents
Methods of Treating Transthyretin (TTR) Mediated Amyloidosis
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Compositions and Methods for Inhibition of Expression of Protein C (Proc) Genes
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid a Gene
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Angiopoietin-Like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Compositions and Methods for Inhibiting Expression of TMPRSS6 Gene
SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Biodegradable Lipids for the Delivery of Active Agents
Patent:
11,246,933 →
Application:
17/302,311 →
Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Endosomal Cleavable Linkers
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Xanthine Dehydrogenase (Xdh) Irna Compositions and Methods of Use Thereof
XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Patent:
11,326,166 →
Application:
17/505,732 →
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Biodegradable Lipids for the Delivery of Active Agents
Biodegradable Lipids for the Delivery of Active Agents
Modified Double-Stranded Rna Agents
MODIFIED RNAi AGENTS
APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Patent:
11,408,001 →
Application:
17/347,863 →
Modified Double-Stranded Rna Agents
STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Modified Double-Stranded Rna Agents
Biodegradable Lipids for the Delivery of Active Agents
Chirally-Enriched Double-Stranded Rna Agents
Biodegradable Lipids for the Delivery of Active Agents
Angiopoietin-Like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Biodegradable Lipids for the Delivery of Active Agents
Biodegradable Lipids for the Delivery of Active Agents
SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
Biodegradable Lipids for the Delivery of Active Agents
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Treating Transthyretin (TTR) Mediated Amyloidosis
Dosages and Methods for Delivering Lipid Formulated Nucleic Acid Molecules
ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Complement Component C3 Irna Compositions and Methods of Use Thereof
ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid a Gene
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Carbohydrate Conjugate Rna Agents and Process for Their Preparation
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Complement Factor B (Cfb) Irna Compositions and Methods of Use Thereof
Compositions and Methods for Inhibiting Expression of the LECT2 Gene
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Extrahepatic Delivery
Tunable Reversir Tm Compounds
GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Xanthine Dehydrogenase (Xdh) Irna Compositions and Methods of Use Thereof
Modified Double-Stranded RNA Agents
Compositions and Methods for Improving Strand Biased
Oligonucleotide-Ligand Conjugates and Process for Their Preparation
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
Multi-Targeted Single Entity Conjugates
Compositions and Methods for Inhibiting Expression of Transthyretin
Biodegradable Lipids for the Delivery of Active Agents
Reversir Tm Compounds
Modified Rna Agents with Reduced Off-Target Effect
Complement Component C3 Irna Compositions and Methods of Use Thereof
Modified RNA Agents with Reduced Off-Target Effect
MODIFIED RNAi AGENTS
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Factor Xii (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) Irna Compositions and Methods of Use Thereof
Biodegradable Lipids for the Delivery of Active Agents
Biodegradable Lipids for the Delivery of Active Agents
Biodegradable Lipids for the Delivery of Active Agents
Complement Component C3 Irna Compositions and Methods of Use Thereof
Modified Double-Stranded Rna Agents
Modified Double-Stranded Rna Agents
Modified Double-Stranded Rna Agents
Coronavirus Irna Compositions and Methods of Use Thereof
Extrahepatic Delivery
Rnai Modulation of Mll-AF4 and Uses Thereof
Rnai Modulation of Apob and Uses Thereof
Oligonucleotides Comprising a Modified or Non-Natural Nucleobase
Chemically Modified Oligonucleotides
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
Oligonucleotides Comprising a Non-Phosphate Backbone Linkage
Single-Stranded and Double-Stranded Oligonucleotides Comprising a 2-Arylpropyl Moiety
Oligonucleotides Comprising a Ligand Tethered to a Modified or Non-Natural Nucleobase
Oligonucleotides Comprising a Conjugate Group Linked Through a C5-Modified Pyrimidine
Rnai Modulation of Mll-AF4 and Uses Thereof
Rnai Modulation of Apob and Uses Thereof
Irna Agents with Biocleavable Tethers
Rnai Modulation of Hif-1 and Therapeutic Uses Thereof
Lipid Formulations
Modified Irna Agents
MODIFIED iRNA AGENTS
Irna Agents with Biocleavable Tethers
MODIFIED iRNA AGENTS
iRNA AGENTS WITH BIOCLEAVABLE TETHERS
iRNA AGENTS WITH BIOCLEAVABLE TETHERS
MODIFIED iRNA AGENTS
iRNA AGENTS WITH BIOCLEAVABLE TETHERS
MODIFIED iRNA AGENTS
Therapeutic Compositions
Therapeutic Compositions
Therapeutic Compositions
Therapeutic Compositions
Therapeutic Compositions
Therapeutic Compositions
Therapeutic Compositions
Therapeutic Compositions
Processes and Reagents for Sulfurization of Oligonucleotides
Process for Desilylation of Oligonucleotides
Oligonucleotides Comprising a Non-Phosphate Backbone Linkage
Oligonucleotides Comprising a Non-Phosphate Backbone Linkage
Chemically Modified Oligonucleotides
Ligand-Conjugated Monomers
Ligand-Conjugated Monomers
Oligonucleotides Comprising a Modified or Non-Natural Nucleobase
Olignucleotides Comprising a Ligand Tethered to a Modified or Non-Natural Nucleobase
Chemically Modified Oligonucleotides for Use in Modulating Micro Rna and Uses Thereof
Compositions and Methods for Inhibiting Expression of Ikk-B Gene
Compositions And Methods For Inhibiting Expression Of IKK-B Gene
Lipid Containing Formulations
Lipid Containing Formulations
Lipid Containing Formulations
Compositions and Methods for Inhibiting Expression of Factor Vii Gene
Compositions and Methods for Inhibiting Expression of Factor Vii Gene
Compositions and Methods for Inhibiting Expression of Factor Vii Gene
Folate Conjugates
Modified Rna Agents with Reduced Off-Target Effect
Patent:
11,504,391 →
Application:
16/461,523 →
2' and 5' Modified Monomers and Oligonucleotides
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
Rna Interference Mediated Inhibition of Myostatin Gene Expression Using Short Interfering Nucleic Acid (Sina)
Lipid Formulation
Irna Agents Targeted to the Rho-a Gene
Modified Irna Agents
Modified Irna Agents
Compositions and Methods for Mediating Rnai in Vivo
Compositions and Methods for Delivering Rnai Using Lipoproteins
Biodegradable Lipids for the Delivery of Active Agents
SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
Compositions and Methods for Inhibiting Expression of the ALAS1 Gene
ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Methods for the Treatment of Subjects Having a Hepatitis B Virus (Hbv) Infection
Nuclease Resistant Double-Stranded Ribonucleic Acid
Nuclease Resistant Double-Stranded Ribonucleic Acid
5'-End Derivatives
Double Stranded Compositions Comprising a 3'-Endo Modified Strand for Use in Gene Modulation
Methods and Compositions for Silencing Genes Without Inducing Toxicity
Compositions and Methods for Inhibiting Expression of a Target Gene
Compositions and Methods for Inhibiting Expression of a Target Gene
Compositions and Methods for Inhibiting Expression of Anti-Apoptotic Genes
Compositions and Methods for Inhibiting Viral Replication
Compositions and Methods for Inhibiting Viral Replication
Compositions and Methods for Inhibiting Expression of a Mutant Gene
Compositions and Methods for Inhibiting Expression of a Mutant Gene
Double-Stranded Rna (Dsrna) and Method of Use for Inhibiting Expression of the Aml-1/MTG8 Fusion Gene
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
Chemically Modified Multifunctional Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Chemically Modified Multifunctional Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
Rna Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
Rna Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Novel Single Chemical Entities and Methods for Delivery of Oligonucleotides
Conjugates and Compositions for Cellular Delivery
Conjugates and Compositions for Cellular Delivery
Conjugates and Compositions for Cellular Delivery
Rna Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Nogo and Nogo Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Nogo and Nogo Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of GRB2 Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of GRB2 Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Matrix Metalloproteinase 13 (MMP13) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Matrix Metalloproteinase 13 (MMP13) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Telomerase Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Stearoyl-Coa Desaturase (Scd) Gene Expression Using Short Interfering Nucelic Acid (Sina)
Rna Interference Mediated Inhibition of Myc and/or Myb Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Myc and/or Myb Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Tnf and Tnf Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Platelet Derived Growth Factor (Pdgf) and Platelet Derived Growth Factor Receptor (Pdgfr) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Fos Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Placental Growth Factor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Hypoxia Inducible Factor 1 (HIF1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Intercellular Adhesion Molecule (Icam) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Stromal Cell-Derived Factor-1 (Sdf-1) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Muscarinic Colinergic Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Vascular Cell Adhesion Molecule (Vcam) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Vascular Cell Adhesion Molecule (Vcam) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of Xiap Gene Expression Using Short Interfering Nucleic Acid (Sina)
Rna Interference Mediated Inhibition of CXCR4 Gene Expression Using Short Interfering Nuceleic Acid (Sina)
RNA Interference Mediated Inhibition of the FC Epsilon R1 Alpha Gene
Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules
Detection and Quantitation of Nucleic Acid Molecules in Biological Samples
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 21, 2017
From: BARTZ, STEVE; BROWN, DUNCAN; ROBINSON, MICHAEL
To: MERCK SHARP & DOHME CORP.
Reel/Frame 044935/0043 →
Assignment of Assignor's Interest
Dec 21, 2017
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 044457/0435 →
Assignment of Assignor's Interest
Apr 26, 2022
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC
Reel/Frame 059729/0423 →
Assignment of Assignor's Interest
Apr 26, 2022
From: BEIGELMAN, LEONID; MCSWIGGEN, JAMES
To: MERCK SHARP & DOHME CORP.
Reel/Frame 059729/0393 →
Assignment of Assignor's Interest
Aug 25, 2022
From: FITZGERALD, KEVIN; TREMBLAY, FREDERIC; MCININCH, JAMES D.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 060895/0300 →
Assignment of Assignor's Interest
Sep 30, 2022
From: KEATING, MARK; MCININCH, JAMES D.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 061271/0787 →
Assignment of Assignor's Interest
Sep 30, 2022
From: TREMBLAY, FREDERIC; MCININCH, JAMES D.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 061271/0734 →
Assignment of Assignor's Interest
Nov 15, 2022
From: NAIR, JAYAPRAKASH K.; MAIER, MARTIN A.; JADHAV, VASANT R.; KEATING, MARK
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 061768/0551 →
Assignment of Assignor's Interest
Dec 7, 2022
From: NAIR, JAYAPRAKASH K.; MAIER, MARTIN A.; JADHAV, VASANT R.; KEATING, MARK
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 062006/0277 →
Assignment of Assignor's Interest
Dec 8, 2022
From: ROGERS, ARLIN; MOBLEY, MELISSA; MCININCH, JAMES D.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 062020/0745 →
Assignment of Assignor's Interest
Dec 15, 2022
From: BOSTWICK, BRET L.; MCININCH, JAMES D.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 062098/0552 →
Assignment of Assignor's Interest
Feb 9, 2023
From: BROWN, CHRISTOPHER; FOSTER, DONALD; ROGERS, ARLIN; JADHAV, VASANT R.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 062644/0392 →
Assignment of Assignor's Interest
Mar 9, 2023
From: MCININCH, JAMES D.; BONDURANT, LUCAS; DEATON, AIMEE; SCHLEGEL, MARK K.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 062928/0233 →
Assignment of Assignor's Interest
Apr 9, 2023
From: MCININCH, JAMES D.; BOSTWICK, BRET LEE; CASTORENO, ADAM
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 063266/0775 →
Assignment of Assignor's Interest
Apr 9, 2023
From: ALNYLAM PHARMACEUTICALS, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 063266/0823 →
Assignment of Assignor's Interest
Apr 9, 2023
From: MCININCH, JAMES D.; BOSTWICK, BRET LEE
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 063266/0770 →
Assignment of Assignor's Interest
Apr 24, 2023
From: NOETZLI, LEILA; PARKER, MARGARET; MCININCH, JAMES D.; SCHLEGEL, MARK K.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 063416/0140 →
Assignment of Assignor's Interest
Apr 24, 2023
From: ROBBIE, GABRIEL; GOEL, VARUN
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 063416/0020 →
Assignment of Assignor's Interest
May 23, 2023
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC
Reel/Frame 063730/0570 →
Assignment of Assignor's Interest
May 23, 2023
From: CARR, BRIAN ALLEN; JADHAV, VASANT R.; KENSKI, DENISE M.; TELLERS, DAVID T.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 063730/0497 →
Assignment of Assignor's Interest
Jun 21, 2023
From: MCGREGOR, TRACY L.; GANSNER, JOHN; BHAN, ISHIR
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 064017/0255 →
Assignment of Assignor's Interest
Sep 22, 2023
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 064992/0442 →
Assignment of Assignor's Interest
Sep 22, 2023
From: BROWN, DUNCAN; CUNNINGHAM, JAMES J.; GINDY, MARIAN; STANTON, MATTHEW G.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 064992/0399 →
Assignment of Assignor's Interest
Dec 22, 2023
From: SOUNDARAPANDIAN, MANGALA MEENAKSHI; DANG, LAN THI HOANG; MCININCH, JAMES D.; SCHLEGEL, MARK K.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 065941/0806 →
Assignment of Assignor's Interest
Mar 12, 2024
From: ASON, BRANDON; BROWN, DUNCAN; STRAPPS, WALTER
To: MERCK SHARP & DOHME CORP.
Reel/Frame 066727/0641 →